3Q 2022 Investor Presentation

Track Record of Successful M&A Delivery Capabilities Acquired Ann't Date Pre- Acquisition Growth1 Post- Acquisition Growth² Target Performance Climate & Natural Disaster Risk Incremental $150M revenue by 2025 ⑪ ON TRACK Projecting MSD sales growth in 2022 Aug 2021 LSD% HSD LDD% Modelling (RMS) AHEAD Accretive to adjusted diluted EPS in 2024 → Projected to be adjusted diluted EPS- accretive in 20233 Screening Capabilities Jan 2020 Mid-teens% Mid-thirties% Double sales to $300M by 20234 (RDC, GRID) AHEAD Projecting to achieve $300M target in 2022 Private Company Data (BvD, ORBIS) May 2017 -10% Mid-teens% ~$80 million in synergies by 2021 EXCEEDED Over $85M in synergies achieved by 2021 1. Note: LSD = low-single-digit; MSD = mid-single-digit; HSD = high-single-digit; LDD = low-double-digit. Approximate three-year Revenue CAGR preceding the acquisition. RMS: 2018-2020; RDC: 2017-2019; BvD: 2014-2016. 2. 3. 4. RMS forecasted to generate $150M in additional revenue, implying HSD - LDD growth, on average, through 2025; RDC and BVD revenue: Trailing twelve months as of June 30, 2022. As stated during Moody's Third Quarter 2022 Earnings Call, on October 25, 2022. Target includes BvD's compliance products. MOODY'S | DECODE RISK. UNLOCK OPPORTUNITY. 3Q 2022 Investor Presentation 13

View entire presentation